CASI Pharmaceuticals, Inc.
CASIF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CASIF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CASIF
CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapeutics in hematology/oncology and autoimmune diseases, currently undergoing a strategic pivot toward CID-103 for organ transplant rejection while managing a going-concern risk with $5.6M cash and a $748.1M accumulated deficit as of 2025-12-31 [sec].
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 5 clinical trials for CASI Pharmaceuticals, Inc..
CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapeutics in hematology/oncology and autoimmune diseases, currently undergoing a strategic pivot toward CID-103 for organ transplant rejection while managing a going-concern risk with $5.6M cash and a $748.1M accumulated deficit as of 2025-12-31 [sec].
- As of December 31, 2025, CASI had cash & equivalents of $5.6M, total revenue of $20.7M, net loss of $48.1M, shareholders' equity of $1.9M, and total debt of $19.2M [sec].
- The company has incurred significant operating losses since inception, with an accumulated deficit of $748.1M as of December 31, 2025, raising substantial doubt about its ability to continue as a going concern [sec].
- On May 9, 2025, CASI entered into a definitive agreement to sell its two wholly-owned subsidiaries in China and transfer certain regional rights to pipeline products BI-1206, CID-103 (Asia excluding Japan), and Thiotepa to an entity wholly-owned by its Chairman [sec].
- Post-transaction, CASI expects to retain rights to CID-103 (Japan and non-Asian regions), EVOMELA, FOLOTYN, CNCT19, and CB-5339, and is accelerating development of CID-103 for organ transplant rejection and autoimmune diseases [sec].
- In August 2025, FDA cleared an IND for CID-103 in active and chronic active renal allograft antibody mediated rejection (AMR); in January 2026, China NMPA approved a CTA for a Phase 1/2 trial of CID-103 in renal allograft AMR [sec].
What works
- CASI has two approved products (EVOMELA and FOLOTYN) generating revenue, providing a commercial base while advancing pipeline candidates [sec].
- CID-103 has received regulatory clearances from both FDA (IND, August 2025) and China NMPA (CTA, January 2026) for Phase 1/2 trials in renal allograft AMR, indicating progress in a new therapeutic area [sec].
- The company is strategically pivoting toward CID-103 for organ transplant rejection and autoimmune diseases, aligning its pipeline with a potentially high-value indication [sec].
What to weigh
- CASI has never generated sufficient revenue to cover expenses and has an accumulated deficit of $748.1M as of December 31, 2025, with a net loss of $48.1M for that year [sec].
- The company's recurring operating losses raise substantial doubt about its ability to continue as a going concern [sec].
- CASI relies on a single source for supply of both EVOMELA and FOLOTYN, creating supply chain risk [sec].
- The proposed acquisition by Chairman Dr. Wei-Wu He at $1.15 per share (announced January 2026) remains unresolved, creating uncertainty about the company's future structure [sec].
From the filings
Quoted directly from source documents.
CASI has incurred significant operating losses and has substantial doubt about going concern.
“Our Recurring Operating Losses have Raised Substantial Doubt Regarding Our Ability to Continue as a Going Concern. Our recurring operating losses raise substantial doubt about our ability to continue as a going concern. Since our inception in 1991, we have incurred significant losses from operations and, as of December 31, 2025, had incurred an accumulated deficit of $748.1 million.”
SEC filings · May 15, 2026
CASI is selling its China subsidiaries and transferring certain pipeline rights.
“On May 9, 2025, the Company entered into a definitive agreement to sell its two wholly-owned subsidiaries in China and to transfer certain regional rights to the pipeline products BI-1206, CID-103 (in Asia excluding Japan) and Thiotepa to an entity wholly-owned by its Chairman and then”
SEC filings · May 15, 2026
CID-103 received FDA IND clearance and China NMPA CTA approval for renal allograft AMR trials.
“In August 2025, we announced FDA clearance of an IND application for CID-103 in adults with active and chronic active renal allograft antibody mediated rejection (AMR). In January 2026, we announced that China NMPA has approved a CTA conduct a Phase 1/2 clinical trial for CID-103 in adults with chronic active renal allograft AMR.”
SEC filings · May 15, 2026
CASI relies on a single source for supply of EVOMELA and FOLOTYN.
“We currently rely on a single source for the supply of both EVOMELA ® and FOLOTYN ® .”
SEC filings · May 15, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Recurring operating losses and accumulated deficit of $748.1M raise substantial doubt about ability to continue as a going concern [sec].
- Single-source supply dependency — CASI relies on a single source for both EVOMELA and FOLOTYN, creating vulnerability to supply disruptions [sec].
- Pending acquisition proposal uncertainty — Chairman's non-binding proposal to acquire outstanding shares at $1.15/share (Jan 2026) remains unresolved, creating strategic uncertainty [sec].
- Dependence on regulatory approvals — Success depends on obtaining and maintaining regulatory approvals for pipeline candidates, which is inherently uncertain [sec].
What to watch
- Resolution of the proposed acquisition by Chairman Dr. Wei-Wu He (no decision made as of May 2026) [sec].
- Progress of CID-103 Phase 1/2 clinical trial in renal allograft AMR (FDA IND cleared Aug 2025, China NMPA CTA approved Jan 2026) [sec].
- Ability to secure additional funding given going concern risk and $5.6M cash position as of Dec 31, 2025 [sec].
- Completion of the sale of China subsidiaries and transfer of pipeline rights (definitive agreement signed May 9, 2025) [sec].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run CASI Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CASI Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
1.2 months
OCF -$21M · Net income -$48M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$25
| Holder | Shares | Value |
|---|---|---|
| simplex trading, llc | 228 | $25 |
Short Interest
as of May 20, 2026- % of float
- 0.5%
- Days to cover
- 2.4
- Shares short
- 90,948
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CASIF short interestFrequently asked questions
What is the AI investment thesis for CASI Pharmaceuticals, Inc.?
CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapeutics in hematology/oncology and autoimmune diseases, currently undergoing a strategic pivot toward CID-103 for organ transplant rejection while managing a going-concern risk with $5.6M cash and a $748.1M accumulated deficit as of 2025-12-31 [sec].
Where is CASI Pharmaceuticals, Inc. headquartered?
CASI Pharmaceuticals, Inc. (CASIF) is headquartered in Beijing, China.
What therapeutic areas does CASI Pharmaceuticals, Inc. focus on?
CASI Pharmaceuticals, Inc. develops therapies across Oncology, Ophthalmology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.